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Introduction
The transition of adult patients with childhood-onset
rheumatic disorders from pediatric to non-pediatric
healthcare systems has received attention in Japan.
However, the clinical course of patients transferred to
non-pediatric rheumatologists has not been adequately
communicated to pediatric rheumatologists.
Objectives
To evaluate the long-term outcome of patients with
juvenile idiopathic arthritis (JIA) using data from a large
cohort database, IORRA (Institute of Rheumatology,
Rheumatoid Arthritis), managed by Tokyo Women’s
Medical University in Japan.
Methods
Of 182 patients identified from the IORRA database
from 2000-2013, 114 were verified as having JIA based
on the ILAR classification criteria. The transition of
medical care, disease activity and health-related quality
of life at the latest examination, and the contributions
of biological disease-modifying antirheumatic drugs
(DMARDs) were evaluated retrospectively.
Results
The mean age of the 114 patients at the latest examination
was 36.6 ± 13.3 years; there were 21 males and 93 females
(81.6%). The mean age at disease onset was 11.6 ± 3.4
years, and disease duration was 25.0 ± 13.3 years. Of the
114 individuals, 106 (93.0%) had poly- or oligoarthritis; the
others had systemic JIA (sJIA). Forty-five of 105 JIA
patients (43%) visited non-pediatric rheumatologists from
disease onset, and only one-fourth were transferred from
general pediatricians or pediatric rheumatologists at a
median age of 20 years. Interestingly, 26 of 105 (25%)
reached transient remission in adolescence. Polyarticular
JIA patients with negative rheumatoid factor (RF) showed
a higher probability (41.7%) of obtaining a transient remis-
sion compared with RF-positive polyarticular JIA patients
(17.8%). Disease activity assessed with DAS28 was signifi-
cantly lower when disease onset was more recent (3.9 ±
1.3 for onset in the 1960s vs. 2.2 ± 1.1 for onset in the
2000s, p = 0.04), with similar results shown on the SDAI,
and the CDAI. The Japanese version of the Health Assess-
ment Questionnaire (J-HAQ) also showed improvement
for those with more recent onset (1.8 ± 1.1 for onset in
the 1960s vs. 0.2 ± 0.4 for onset in the 2000s, p<0.01). The
induction ratio of biological DMARDs has increased
for patients with more recent disease onset, with a shorter
period from disease onset to induction (16.7% in the
1970s, with 27.3 ± 2.1 years to induction vs. 80.0% in
the 2000s, with 5.6 ± 2.3 years to induction). Additionally,
the percentage of patients requiring orthopedic surgery
has decreased (53.8% before the 1970s vs. 10.0% in the
2000s). Two deaths, with causality attributed to the
primary disease, occurred in sJIA patients who died from
renal and/or cardiac failure due to amyloidosis at the ages
of 27 and 38.
Conclusion
From the viewpoint of pediatric rheumatologists, there are
few opportunities to follow children beyond adolescence.
The importance of transitioning care to non-pediatric
rheumatologists with sufficient medical information is
confirmed by the existence of a population with transient
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remission in adolescence and changes in their prognosis,
with progress in rheumatology represented by biological
DMARDs.
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